Pfizer Inc. reported first-quarter results that beat Wall Street forecasts, driven by strong momentum in newer and recently acquired products [1].
This performance marks a critical transition for the company as it seeks to replace the massive revenue streams generated by COVID-19 vaccines and treatments. By diversifying its portfolio through acquisitions, the company is attempting to mitigate the impact of declining pandemic-related sales and upcoming patent expirations.
The New York-based pharmaceutical company saw growth from recently launched products help offset near-term loss-of-exclusivity pressures [2]. According to reports, the company's adjusted earnings per share for the first quarter of 2024 were $0 [3].
Pfizer has provided revenue guidance for 2026 ranging from $59.5 billion to $62.5 billion [4]. This outlook reflects the company's strategy to stabilize its financial position before targeting a more aggressive growth phase in the late 2020s.
Looking further ahead, the company has indicated visibility for a high single-digit compound annual growth rate after 2028 [5]. This long-term return to growth is pinned on the development and rollout of new drugs targeting obesity and cancer [5].
The company reaffirmed its full-year outlook during the earnings release, saying that the current trajectory of its new product pipeline is meeting internal expectations [1].
“Pfizer reported first-quarter results that beat Wall Street forecasts”
Pfizer is currently in a high-stakes pivot. After the unprecedented windfall of the pandemic era, the company must prove it can sustain growth through organic innovation and strategic acquisitions. The focus on obesity and oncology drugs represents a shift toward chronic disease markets, which offer more stable, long-term revenue than the volatile vaccine market.
